See more : Tata Metaliks Limited (TATAMETALI.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Achieve Life Sciences, Inc. (ACHV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Achieve Life Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Allegiance Coal Limited (AHQ.AX) Income Statement Analysis – Financial Results
- YanGuFang International Group Co., Ltd. (YGFGF) Income Statement Analysis – Financial Results
- Princeton National Bancorp, Inc. (PNBC) Income Statement Analysis – Financial Results
- Parkin Company P.J.S.C. (PARKIN.AE) Income Statement Analysis – Financial Results
- Unionman Technology Co., Ltd. (688609.SS) Income Statement Analysis – Financial Results
Achieve Life Sciences, Inc. (ACHV)
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.06M | 18.16M | 27.12M | 29.88M | 20.10M | 5.50M | 13.62M | 25.54M | 20.13M | 20.13M | 22.39M | 8.25M | 264.96M | 25.00K | 25.00K | 8.75M | 408.41K | 12.10M | 5.10M | 18.90M | 16.60M | 4.50M | 1.10M |
| Cost of Revenue | 228.00K | 236.00K | 250.00K | 255.00K | 254.00K | 282.00K | 282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.22M | 3.69M | -600.00K | -800.00K | -600.00K | -500.00K | -300.00K | 5.50M |
| Gross Profit | -228.00K | -236.00K | -250.00K | -255.00K | -254.00K | -282.00K | -282.00K | 5.06M | 18.16M | 27.12M | 29.88M | 20.10M | 5.50M | 13.62M | 25.54M | 20.13M | 20.13M | 22.39M | 8.25M | 264.96M | 25.00K | 25.00K | 3.53M | -3.28M | 12.70M | 5.90M | 19.50M | 17.10M | 4.80M | -4.40M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 40.33% | -803.51% | 104.96% | 115.69% | 103.17% | 103.01% | 106.67% | -400.00% |
| Research & Development | 15.81M | 30.08M | 23.97M | 6.88M | 9.67M | 5.87M | 3.10M | 14.79M | 25.11M | 46.22M | 55.32M | 39.95M | 21.55M | 18.48M | 24.16M | 7.82M | 27.15M | 41.10M | 24.49M | 10.71M | 7.65M | 8.96M | 5.22M | 3.26M | 5.60M | 10.50M | 11.60M | 11.20M | 7.20M | 0.00 |
| General & Administrative | 11.44M | 10.72M | 9.13M | 7.87M | 6.85M | 6.95M | 3.53M | 8.93M | 11.81M | 10.63M | 9.89M | 7.79M | 0.00 | 5.84M | 3.96M | 3.29M | 8.22B | 7.58B | 5.57B | 5.87B | 3.01B | 3.24B | 3.31M | 3.95M | 5.78M | 6.55M | 7.20M | 3.81M | 2.20M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.21B | -7.57B | -5.56B | -5.86B | -3.01B | -3.24B | 888.00 | 432.52K | 720.00K | -50.00K | 0.00 | -10.00K | 0.00 | 0.00 |
| SG&A | 11.44M | 10.72M | 9.13M | 7.87M | 6.85M | 6.95M | 3.53M | 8.93M | 11.81M | 10.63M | 9.89M | 7.79M | 6.23M | 5.84M | 3.96M | 3.29M | 8.22M | 7.58M | 5.57M | 5.87M | 3.01M | 3.24M | 3.31M | 4.38M | 6.50M | 6.50M | 7.20M | 3.80M | 2.20M | 3.50M |
| Other Expenses | 0.00 | -1.55M | -58.00K | -49.00K | 133.00K | 126.00K | 165.00K | 1.06M | 1.95M | 3.23M | 120.00K | 138.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 600.00K | 800.00K | 600.00K | 500.00K | 400.00K | 300.00K |
| Operating Expenses | 27.02M | 40.80M | 33.09M | 14.75M | 16.53M | 12.81M | 6.63M | 23.72M | 36.91M | 56.85M | 65.21M | 47.74M | 27.78M | 24.32M | 28.12M | 11.11M | 35.37M | 48.68M | 30.06M | 16.58M | 10.66M | 12.20M | 8.53M | 7.64M | 12.70M | 17.80M | 19.40M | 15.50M | 9.80M | 3.80M |
| Cost & Expenses | 27.25M | 40.80M | 33.09M | 14.75M | 16.53M | 12.81M | 6.63M | 23.72M | 36.91M | 56.85M | 65.21M | 47.74M | 27.78M | 24.32M | 28.12M | 11.11M | 35.37M | 48.68M | 30.06M | 16.58M | 10.66M | 12.20M | 8.53M | 7.64M | 12.10M | 17.00M | 18.80M | 15.00M | 9.50M | 9.30M |
| Interest Income | 825.00K | 199.00K | 17.00K | 69.00K | 170.00K | 171.00K | 21.00K | 203.00K | 119.00K | 35.00K | 150.00K | 292.00K | 220.00K | 86.00K | 47.00K | 210.00K | 2.30M | 2.85M | 714.87K | 289.59K | 213.19K | 468.48K | 539.69K | 692.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.85M | 1.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 531.00K | 0.00 | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 | 434.00 | 2.98K | 6.82K | 24.63K | 42.14K | 31.67K | 13.86K | 34.06K | 470.00K | 200.00K | 970.00K | 200.00K | 800.00K | 600.00K |
| Depreciation & Amortization | 228.00K | 236.00K | 250.00K | 255.00K | 254.00K | 282.00K | 282.00K | 188.00K | 244.00K | 223.00K | 227.00K | 100.00K | 75.00K | 52.00K | 50.00K | 89.00K | 655.69K | 609.62K | 586.16K | 515.48K | 380.43K | 580.62K | 258.10K | 357.54K | 600.00K | 800.00K | 600.00K | 500.00K | 400.00K | 300.00K |
| EBITDA | -26.73M | -40.33M | -32.90M | -14.48M | -16.14M | -12.41M | -13.35M | -19.94M | -16.56M | -26.02M | -31.62M | -21.00M | -22.21M | -15.53M | 1.42M | -10.60M | -12.41M | -22.94M | -20.50M | -15.73M | -10.26M | -11.59M | 474.45K | -6.88M | 589.54K | -11.08M | 700.00K | 2.10M | -4.60M | -7.90M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -318.57% | -103.27% | -110.64% | -128.20% | -167.50% | -538.68% | -41.80% | -10.57% | -55.80% | -71.80% | -114.17% | -257.16% | -6.06% | -41,030.90% | -46,373.91% | 5.42% | -2,724.05% | 12.40% | -237.25% | -2.12% | 7.83% | -108.89% | -727.27% |
| Operating Income | -27.25M | -40.80M | -33.09M | -14.75M | -16.53M | -12.81M | -6.63M | -21.19M | -18.75M | -29.47M | -35.33M | -25.99M | -22.29M | -14.75M | -2.47M | -6.26M | -15.23M | -26.29M | -21.81M | -16.58M | -10.64M | -12.17M | 216.35K | -7.23M | 900.00K | -11.90M | 100.00K | 1.60M | -5.00M | -8.20M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -418.65% | -103.27% | -108.67% | -118.22% | -129.32% | -405.51% | -108.29% | -9.65% | -31.11% | -75.68% | -117.39% | -264.21% | -6.26% | -42,552.60% | -48,696.39% | 2.47% | -1,770.96% | 7.44% | -233.33% | 0.53% | 9.64% | -111.11% | -745.45% |
| Total Other Income/Expenses | -2.57M | -1.55M | -58.00K | 20.00K | 133.00K | 126.00K | -7.00M | -1.47M | 1.95M | 3.49M | 3.48M | 6.55M | 7.61M | -4.88M | 117.00K | 421.00K | 2.17M | 2.74M | 712.20K | -735.04K | 171.05K | 436.81K | 525.83K | 4.91M | 440.46K | 711.22K | 1.00M | 600.00K | -400.00K | -500.00K |
| Income Before Tax | -29.82M | -42.35M | -33.15M | -14.73M | -16.40M | -12.69M | -13.63M | -20.13M | -16.80M | -26.24M | -31.85M | -21.10M | -14.67M | -15.58M | 2.47M | -10.69M | -15.36M | -26.40M | -21.81M | -16.31M | -10.47M | -11.74M | 742.18K | -2.32M | 430.00K | -11.17M | 1.10M | 2.20M | -5.40M | -8.70M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -397.65% | -92.52% | -96.77% | -106.58% | -104.99% | -266.98% | -114.45% | 9.65% | -53.11% | -76.30% | -117.90% | -264.16% | -6.16% | -41,868.40% | -46,949.14% | 8.48% | -569.13% | 3.55% | -219.02% | 5.82% | 13.25% | -120.00% | -790.91% |
| Income Tax Expense | 0.00 | -475.00K | -250.00K | -69.00K | -254.00K | -126.00K | -3.05M | -1.06M | -1.95M | -3.49M | -3.48M | -6.55M | -7.61M | -3.00M | -3.01M | -2.06M | -2.17M | -2.74M | -712.20K | -264.96K | -171.05K | -101.48K | 200.00K | -176.94K | 470.00K | -730.00K | 100.00K | 500.00K | 500.00K | 200.00K |
| Net Income | -29.82M | -41.88M | -32.90M | -14.66M | -16.14M | -12.69M | -10.58M | -20.13M | -16.80M | -26.24M | -31.85M | -21.10M | -14.67M | -12.58M | 5.48M | -4.20M | -13.06M | -23.55M | -21.10M | -16.31M | -10.47M | -11.64M | 542.18K | -2.15M | 400.00K | -11.20M | 1.00M | 1.70M | -5.90M | -8.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -397.65% | -92.52% | -96.77% | -106.58% | -104.99% | -266.98% | -92.42% | 21.44% | -20.88% | -64.89% | -105.18% | -255.58% | -6.16% | -41,868.40% | -46,543.20% | 6.20% | -525.81% | 3.31% | -219.61% | 5.29% | 10.24% | -131.11% | -809.09% |
| EPS | -1.50 | -3.95 | -4.05 | -5.39 | -39.15 | -72.29 | -441.47 | -1.48K | -1.41K | -3.19K | -4.77K | -3.43K | -3.32K | -3.94K | 1.91K | -1.68K | -13.97K | -25.32K | -27.36K | -30.26K | -23.11K | -33.73K | 1.84K | -8.87K | 1.91K | -51.61K | 4.61K | 7.91K | -27.70K | -41.78K |
| EPS Diluted | -1.50 | -3.95 | -4.05 | -5.39 | -39.15 | -72.29 | -441.47 | -1.47K | -1.41K | -3.19K | -4.77K | -3.43K | -3.32K | -3.94K | 1.91K | -1.68K | -13.97K | -25.32K | -27.36K | -30.26K | -23.11K | -33.73K | 1.84K | -8.87K | 1.91K | -51.61K | 4.61K | 7.91K | -27.70K | -41.78K |
| Weighted Avg Shares Out | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 13.61K | 11.89K | 8.23K | 6.67K | 6.15K | 4.42K | 3.20K | 2.58K | 2.51K | 935.00 | 930.00 | 771.00 | 539.00 | 453.00 | 345.00 | 294.00 | 242.00 | 227.00 | 217.00 | 217.00 | 215.00 | 213.00 | 213.00 |
| Weighted Avg Shares Out (Dil) | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 13.65K | 11.89K | 8.23K | 6.67K | 6.15K | 4.42K | 3.20K | 2.58K | 2.51K | 935.00 | 930.00 | 771.00 | 539.00 | 453.00 | 345.00 | 294.00 | 242.00 | 227.00 | 217.00 | 217.00 | 215.00 | 213.00 | 213.00 |
Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns
Achieve Life Sciences is working to commercialize the smoking cessation drug Cytisinicline, which has shown promising results in clinical trials. The drug has a superior safety profile compared to existing treatment options and has the potential to address a large...
Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript
Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024 Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve...
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
Open-label exposure trial expected to initiate in Q2'24 with NDA filing anticipated in 1H 2025 Open-label exposure trial expected to initiate in Q2'24 with NDA filing anticipated in 1H 2025
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants
Why Is Achieve Life Sciences (ACHV) Stock Down 25% Today?
Achieve Life Sciences (NASDAQ: ACHV ) stock is dropping on Tuesday after the company provided an update on its New Drug Application (NDA) for cytisinicline. A meeting with the Food and Drug Administration (FDA) saw the agency request additional data concerning...
Achieve Life Sciences shares drop as analysts see delayed launch of smoking-cessation treatment
Achieve Life Sciences Inc. shares ACHV, -1.09% dropped 25% premarket on Tuesday as analysts forecasted delays in the launch of the company's smoking cessation treatment cytisinicline. In a recent meeting with the U.S. Food and Drug Administration, the agency said...
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve...
Achieve Life Sciences, Inc. (ACHV) Q3 2023 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Nicole Jones - IR John Bencich - CEO Jerry Wan - Principal Accounting Officer Cindy Jacobs - President and CMO Conference...
Source: https://incomestatements.info
Category: Stock Reports